Dry Needling Versus Stretching for Muscle Extensibility

Comparing Dry Needling and Stretching for the Management of Muscle Extensibility in Patients With Hip Osteoarthritis: A Randomized Clinical Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04400825

Enrollment

Registered

2020-05-26

Start date

2020-05-01

Completion date

2020-07-19

Last updated

2020-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Hip

Keywords

physiotherapy, stretching, dry needling

Brief summary

Hip osteoarthritis (OA) is one of the most prevalent chronic disease in the world. Currently several authors have shown the presence of active myofascial trigger points (MTrP) in the muscles surrounding the hip joint that reproduce the symptoms of the patients with hip OA. Despite of the beneficial effects that have shown may conservative non-pharmacological treatments, there is a lack of studies evaluating the effects of the conservative treatments on muscle extensibility. According to the new paradigm about the presence of MTrPs, the investigators decided to conduct a randomized clinical trial to compare the effects of DN intervention and stretching protocol on muscle extensibility in patients with hip OA.

Interventions

OTHERDry needling

Dry needling of the active MTrPs following the technique described by Hong et al (1994,1995)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Masking description

single-blind

Intervention model description

randomized clinical trial

Eligibility

Sex/Gender

ALL

Age

50 Years to 70 Years

Healthy volunteers

Inclusion criteria

* unilateral hip OA diagnosed medically with a X-Ray tess and following the American College of Rheumatology Criteria

Exclusion criteria

* Secondary osteoarthritis by a traumatism, Paget disease, inflammatory or metabolic disease, congenital diseases etc. * Vascular or neurological disease. * Musculoskeletal pathologies in lumbar spine, pelvis or lower limbs * DN contraindications or fear of needles

Design outcomes

Primary

Measure	Time frame	Description
muscle extensibility	Baseline	the examiners assess the muscle extensibility using an inclinomenter

Secondary

Measure	Time frame	Description
Stiffness	Baseline	the examiners assess the stiffness using the WOMAC stiffness subscale

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026